分子感染症検査市場は、2024年の93億7000万ドルから2029年には177億8000万ドルに成長し、予測期間中のCAGRは13.7%になると予想されます。この市場で活動している主要なプレーヤーは、Danaher(米国)、F. Hoffmann-La Roche Ltd(スイス)、bioMérieux(フランス)、Hologic、Inc.(米国)、Abbott(米国)、Thermo Fisher Scientific Inc.(米国)、QIAGEN(オランダ)、Revvity(米国)、Siemens Healthineers AG(ドイツ)、BD(米国)、Grifols、SA(スペイン)、QuidelOrtho Corporation(米国)、DiaSorin S.p.A.(イタリア)、Bruker(米国)、Seegene Inc.(韓国)、Genetic Signatures(オーストラリア)、Co-Diagnostics、 Inc.(米国)、Savyon Diagnostics(イスラエル)、Vela Diagnostics(シンガポール)、Molbio Diagnostics Pvt. Ltd.(インド)、Uniogen OY(フィンランド)、geneOmbio Technologies(インド)、Advanced Molecular Diagnostics(英国)、GeneFirst Limited(英国)、altona Diagnostics GmbH(ドイツ)
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key secondary sources
2.2.1.2 Key data from secondary sources
2.2.1.3 Objectives of secondary research
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Objectives of primary research
2.2.2.4 Key industry insights
2.2.2.5 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Company revenue estimation approach
2.3.1.2 Presentations of companies and primary interviews
2.3.1.3 Estimation of total molecular-based tests for HIV in US
2.3.1.4 Growth forecast model
2.3.1.5 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 RESEARCH ASSUMPTIONS
2.6.1 PARAMETRIC ASSUMPTIONS
2.6.2 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW
4.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
4.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029
4.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029
4.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029
4.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029
4.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029
4.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising burden of infectious diseases
5.2.1.2 Rapid technological advancements in molecular diagnostics
5.2.1.3 Growing funding for molecular testing
5.2.2 RESTRAINTS
5.2.2.1 Inconsistent reimbursement policies
5.2.3 OPPORTUNITIES
5.2.3.1 High growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers and labor shortage issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT
5.4.2 INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER
5.4.3 INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL DISEASE TESTS, BY KEY PLAYER
5.4.4 INDICATIVE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Polymerase chain reaction
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Isolated nucleic acid amplification technology
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Next-generation sequencing
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 3822
5.11.2 EXPORT DATA FOR HS CODE 3822
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1: IMPROVED PATHOGEN-DIRECTED TREATMENT THROUGH RAPID SYNDROMIC PCR TESTING
5.13.2 CASE STUDY 2: CLINICAL IMPACT OF MULTIPLEX MOLECULAR DIAGNOSTIC TESTING IN CHILDREN WITH ACUTE GASTROENTERITIS
5.13.3 CASE STUDY 3: IMPACT OF MOLECULAR POINT OF CARE TESTING FOR GROUP A STREPTOCOCCUS PHARYNGITIS
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 NORTH AMERICA
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 EUROPE
5.14.1.2.1 Germany
5.14.1.2.2 UK
5.14.1.2.3 France
5.14.1.2.4 Italy
5.14.1.3 ASIA PACIFIC
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.1.3.4 Australia
5.14.1.4 LATIN AMERICA
5.14.1.4.1 Brazil
5.14.1.4.2 Mexico
5.14.1.5 MIDDLE EAST
5.14.1.5.1 Africa
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER'S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 BUYING CRITERIA
5.17 IMPACT OF AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING APPLICATIONS
5.17.3 AI USE CASES
5.17.4 KEY COMPANIES IMPLEMENTING AI
5.17.5 FUTURE OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH
6.3 INSTRUMENTS
6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FOSTER GROWTH
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH
7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE
7.1 INTRODUCTION
7.2 MULTIPLEX TESTING
7.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH
7.3 SINGLEPLEX TESTING
7.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH
8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE
8.1 INTRODUCTION
8.2 LABORATORY TESTS
8.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH
8.3 POINT OF CARE TESTS
8.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET
9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE
9.1 INTRODUCTION
9.2 RESPIRATORY INFECTIOUS DISEASES
9.2.1 INFLUENZA
9.2.1.1 Growing focus on faster diagnosis and control to propel market
9.2.2 TUBERCULOSIS
9.2.2.1 Rise in undiagnosed and untreated cases to promote growth
9.2.3 PHARYNGITIS
9.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth
9.2.4 OTHER RESPIRATORY INFECTIOUS DISEASES
9.3 GASTROINTESTINAL INFECTIOUS DISEASES
9.3.1 HEPATITIS
9.3.1.1 Rising government initiatives to expedite growth
9.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES
9.4 SEXUALLY TRANSMITTED DISEASES
9.4.1 HUMAN IMMUNODEFICIENCY VIRUS
9.4.1.1 Increasing number of blood transfusions and blood donations to augment growth
9.4.2 HUMAN PAPILLOMAVIRUS
9.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market
9.4.3 CHLAMYDIA TRACHOMATIS
9.4.3.1 Increasing development of molecular tests to aid growth
9.4.4 NEISSERIA GONORRHOEAE
9.4.4.1 Increasing development of novel assays to boost market
9.4.5 SYPHILIS
9.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
9.4.6 OTHER SEXUALLY TRANSMITTED DISEASES
9.5 HOSPITAL-ACQUIRED INFECTIONS
9.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET
9.6 VAGINITIS
9.6.1 INCREASING AWARENESS ABOUT WOMEN'S HEALTH TO BOLSTER GROWTH
9.7 MENINGITIS
9.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH
9.8 VECTOR-BORNE DISEASES
9.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET
9.9 OTHER INFECTIOUS DISEASES
10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 POLYMERASE CHAIN REACTION
10.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
10.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
10.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH
10.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
10.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
10.5 IN SITU HYBRIDIZATION
10.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET
10.6 DNA MICROARRAYS
10.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH
10.7 OTHER TECHNOLOGIES
11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER
11.1 INTRODUCTION
11.2 DIAGNOSTIC LABORATORIES
11.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
11.3 HOSPITALS & CLINICS
11.3.1 RISING PATIENT VOLUME TO CONTRIBUTE TO GROWTH
11.4 OTHER END USERS
12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Presence of advanced healthcare infrastructure to augment growth
12.2.3 CANADA
12.2.3.1 Favorable government initiatives to fuel market
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing healthcare expenditure to advance growth
12.3.3 UK
12.3.3.1 Growing number of diagnostic centers to fuel market
12.3.4 FRANCE
12.3.4.1 Increasing demand for early disease diagnosis to augment growth
12.3.5 ITALY
12.3.5.1 Growing adoption of advanced diagnostic technologies to fuel market
12.3.6 RUSSIA
12.3.6.1 Increasing access to quality healthcare to facilitate growth
12.3.7 SPAIN
12.3.7.1 Growing public health initiatives to boost market
12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rising public access to modern healthcare to spur growth
12.4.3 JAPAN
12.4.3.1 Universal healthcare reimbursement policy to foster growth
12.4.4 INDIA
12.4.4.1 Increased private and public investments to bolster growth
12.4.5 AUSTRALIA
12.4.5.1 Growing investments for testing centers and treatment facilities to drive market
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing focus on improving healthcare infrastructure to fuel market
12.5.3 MEXICO
12.5.3.1 Increasing accessibility and affordability of healthcare services to foster growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12.7 GCC COUNTRIES
12.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET
12.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
13.3 REVENUE ANALYSIS, 2021-2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 MARKET SHARE ANALYSIS OF EMEA REGION, 2023
13.6 COMPANY VALUATION AND FINANCIAL METRICS
13.7 BRAND/PRODUCT COMPARISON
13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.8.1 STARS
13.8.2 EMERGING LEADERS
13.8.3 PERVASIVE PLAYERS
13.8.4 PARTICIPANTS
13.8.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
13.8.5.1 Company footprint
13.8.5.2 Region footprint
13.8.5.3 Product & service footprint
13.8.5.4 Test type footprint
13.8.5.5 Disease footprint
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.9.1 PROGRESSIVE COMPANIES
13.9.2 RESPONSIVE COMPANIES
13.9.3 DYNAMIC COMPANIES
13.9.4 STARTING BLOCKS
13.9.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023
13.9.5.1 Detailed list of key startups/SMEs
13.9.5.2 Competitive benchmarking of startups/SMEs
13.10 COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES AND APPROVALS
13.10.2 DEALS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 DANAHER
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches and approvals
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Right to win
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 F. HOFFMANN-LA ROCHE LTD
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches and approvals
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Right to win
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 BIOMERIEUX
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.4 MnM view
14.1.3.4.1 Right to win
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 HOLOGIC, INC.
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Right to win
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 ABBOTT
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Right to win
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 THERMO FISHER SCIENTIFIC INC.
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 QIAGEN
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Expansions
14.1.8 REVVITY
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.9 GRIFOLS, S.A.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.9.3.2 Deals
14.1.10 SEEGENE INC.
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.10.3.3 Expansions
14.1.11 DIASORIN S.P.A.
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches and approvals
14.1.11.3.2 Deals
14.1.12 SIEMENS HEALTHINEERS AG
14.1.12.1 Business overview
14.1.12.2 Products offeredn
14.1.12.3 Recent developments
14.1.12.3.1 Product launches and approvals
14.1.12.3.2 Deals
14.1.12.3.3 Expansions
14.1.13 BD
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.13.3.3 Expansions
14.2 OTHER PLAYERS
14.2.1 QUIDELORTHO CORPORATION
14.2.2 BRUKER
14.2.3 GENETIC SIGNATURES
14.2.4 CO-DIAGNOSTICS, INC.
14.2.5 VELA DIAGNOSTICS
14.2.6 MOLBIO DIAGNOSTICS PVT. LTD.
14.2.7 SAVYON DIAGNOSTICS
14.2.8 UNIOGEN OY
14.2.9 GENEOMBIO TECHNOLOGIES
14.2.10 ADVANCED MOLECULAR DIAGNOSTICS
14.2.11 ALTONA DIAGNOSTICS GMBH
14.2.12 GENEFIRST LIMITED
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
